Virological outcomes of EVG/COBI/FTC/TDF and EVG/COBI/FTC/TAF in antiretroviral-naive HIV-1-infected participants with baseline HIV-1 RNA >= 1,000,000 copies/ml: a post hoc analysis of Phase 3 clinical trials